



March 10, 2016

Press release

Mitsubishi Tanabe Pharma Corporation

**Notice regarding change of current commercialization scheme to new strategic
co-promotion partnership in Japan for RA treatment agent
Simponi[®] subcutaneous injection 50 mg syringe (generic name: golimumab)**

Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka; President & Representative Director: Masayuki Mitsuka) and Janssen Biotech, Inc., of the U.S., announced today that they have concluded a revised agreement for the commercialization of Simponi[®] subcutaneous injection 50 mg syringe (generic name: golimumab) in Japan. This change will take effect from April 1, 2016. Under the new strategy, the distribution of Simponi[®] will be undertaken solely by Mitsubishi Tanabe Pharma. This will facilitate new strategic co-promotion initiatives by the two companies.

Even after the change takes effect, Mitsubishi Tanabe Pharma and Janssen Pharmaceutical K.K (Head Office: Chiyoda-ku, Tokyo; President: Chris Hourigan) will continue to jointly implement promotional activities for Simponi[®].

In the future, both companies will continue to make full use of their specialized expertise and do their utmost to rapidly meet the needs of healthcare professionals and patients.

This change in the agreement will contribute to the reinforcement of domestic commercialization initiatives in the field of autoimmune diseases, which is one of Mitsubishi Tanabe Pharma's priority disease areas. Moving forward, Mitsubishi Tanabe Pharma will continue to aggressively develop and market pharmaceuticals that address unmet medical needs.

End

⟨⟨For Details, Contact the Following Section⟩⟩
Corporate Communications Department
Tel +81-6-6205-5211